Portfolio company Calluna Pharma completed patient enrollment in its IPF (idiopathic pulmonary fibrosis) development program.
Calluna Pharma is a global clinical-stage biotechnology company pioneering a breakthrough approach to treating inflammatory and fibrotic diseases by leveraging the body’s innate immune system
Calluna Pharma is a global clinical-stage biotechnology company pioneering a breakthrough approach to treating inflammatory and fibrotic diseases by leveraging the body’s innate immune system. The company has a robust pipeline of selective antibodies targeting immunological diseases with enhanced efficacy.